References
Key articles
Abrams DJ, Rojas DC, Arciniegas DB. Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature. Neuropsychiatr Dis Treat. 2008 Dec;4(6):1089-109.Full text Abstract
Harrow M, Grossman LS, Herbener ES, et al. Ten-year outcome: patients with schizoaffective disorders, schizophrenia, affective disorders and mood-incongruent psychotic symptoms. Br J Psychiatry. 2000 Nov;177:421-6.Full text Abstract
Cheniaux E, Landeira-Fernandez J, Versiani M. The diagnoses of schizophrenia, schizoaffective disorder, bipolar disorder and unipolar depression: interrater reliability and congruence between DSM-IV and ICD-10. Psychopathology. 2009;42(5):293-8. Abstract
Jäger M, Haack S, Becker T, et al. Schizoaffective disorder: an ongoing challenge for psychiatric nosology. Eur Psychiatry. 2011 Apr;26(3):159-65. Abstract
Turner DT, van der Gaag M, Karyotaki E, et al. Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. Am J Psychiatry. 2014 May;171(5):523-38. Abstract
National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. March 2014 [internet publication].Full text
Reference articles
1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Association; 2022.
2. World Health Organization. ICD-11 for mortality and morbidity statistics. Feb 2022 [internet publication].Full text
3. Marneros A, Deister A, Rohde A. Psychopathological and social status of patients with affective, schizophrenic and schizoaffective disorders after long-term course. Acta Psychiatr Scand. 1990 Nov;82(5):352-8. Abstract
4. Abrams DJ, Rojas DC, Arciniegas DB. Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature. Neuropsychiatr Dis Treat. 2008 Dec;4(6):1089-109.Full text Abstract
5. Perala J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007 Jan;64(1):19-28.Full text Abstract
6. Scully PJ, Owens JM, Kinsella A, et al. Schizophrenia, schizoaffective and bipolar disorder within an epidemiologically complete, homogeneous population in rural Ireland: small area variation in rate. Schizophr Res. 2004 Apr 1;67(2-3):143-55. Abstract
7. Ayano G, Tesfaw G, Shumet S. The prevalence of schizophrenia and other psychotic disorders among homeless people: a systematic review and meta-analysis. BMC Psychiatry. 2019 Nov 27;19(1):370.Full text Abstract
8. Azorin JM, Kaladjian A, Fakra E. Current issues on schizoaffective disorder [in French]. Encephale. 2005 May-Jun;31(3):359-6. Abstract
9. Hamshere ML, Bennett P, Williams N, et al. Genomewide linkage scan in schizoaffective disorder: significant evidence for linkage at 1q42 close to DISC1, and suggestive evidence at 22q11 and 19p13. Arch Gen Psychiatry. 2005 Oct;62(10):1081-8.Full text Abstract
10. Lencz T, Lipsky RH, DeRosse P, et al. Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes. Br J Psychiatry. 2009 Apr;194(4):313-8.Full text Abstract
11. Meltzer HY, Arora RC, Metz J. Biological studies of schizoaffective disorders. Schizophr Bull. 1984;10(1):49-70. Abstract
12. Westermeyer J. Comorbid schizophrenia and substance abuse: a review of epidemiology and course. Am J Addict. 2006 Sep-Oct;15(5):345-55. Abstract
13. Caton CL, Samet S, Hasin DS. When acute-stage psychosis and substance use co-occur: differentiating substance-induced and primary psychotic disorders. J Psychiatr Pract. 2000 Sep;6(5):256-66. Abstract
14. Gregg L, Barrowclough C, Haddock G. Reasons for increased substance use in psychosis. Clin Psychol Rev. 2007 May;27(4):494-510. Abstract
15. Sipos A, Rasmussen F, Harrison G, et al. Paternal age and schizophrenia: a population based cohort study. BMJ. 2004 Nov 6;329(7474):1070.Full text Abstract
16. Corcoran C, Walker E, Huot R, et al. The stress cascade and schizophrenia: etiology and onset. Schizophr Bull. 2003;29(4):671-92. Abstract
17. Morgan C, Fisher H. Environment and schizophrenia: environmental factors in schizophrenia: childhood trauma - a critical review. Schizophr Bull. 2007 Jan;33(1):3-10.Full text Abstract
18. Tsuang MT, Stone WS, Faraone SV. Understanding predisposition to schizophrenia: toward intervention and prevention. Can J Psychiatry. 2002 Aug;47(6):518-26. Abstract
19. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull. 1996;22(2):353-70. Abstract
20. Stafford MR, Jackson H, Mayo-Wilson E, et al. Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ. 2013 Jan 18;346:f185.Full text Abstract
21. McGrath J, Emmerson WB. Fortnightly review. Treatment of schizophrenia. BMJ. 1999 Oct 16;319(7216):1045-8.Full text Abstract
22. Harding CM. Course types in schizophrenia: an analysis of European and American studies. Schizophr Bull. 1988;14(4):633-43. Abstract
23. Ciompi L. Catamnestic long-term study on the course of life and aging of schizophrenics. Schizophr Bull. 1980;6(4):606-18. Abstract
24. Howes OD, Whitehurst T, Shatalina E, et al. The clinical significance of duration of untreated psychosis: an umbrella review and random-effects meta-analysis. World Psychiatry. 2021 Feb;20(1):75-95.Full text Abstract
25. Correll CU, Galling B, Pawar A, et al. Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression. JAMA Psychiatry. 2018 Jun 1;75(6):555-65.Full text Abstract
26. Puntis S, Minichino A, De Crescenzo F, et al. Specialised early intervention teams for recent-onset psychosis. Cochrane Database Syst Rev. 2020 Nov 2;11(11):CD013288.Full text Abstract
27. Puntis S, Minichino A, De Crescenzo F, et al. Specialised early intervention teams (extended time) for recent-onset psychosis. Cochrane Database Syst Rev. 2020 Nov 2;11(11):CD013287.Full text Abstract
28. Dazzan P, Murray RM. Neurological soft signs in first-episode psychosis: a systematic review. Br J Psychiatry. 2002 Sep;43:s50-7. Abstract
29. Tosato S, Dazzan P. The psychopathology of schizophrenia and the presence of neurological soft signs: a review. Curr Opin Psychiatry. 2005 May;18(3):285-8. Abstract
30. Ferruccio NP, Tosato S, Lappin JM, et al. Neurological signs at the first psychotic episode as correlates of long-term outcome: results from the AESOP-10 study. Schizophr Bull. 2021 Jan 23;47(1):118-27.Full text Abstract
31. Harrow M, Grossman LS, Herbener ES, et al. Ten-year outcome: patients with schizoaffective disorders, schizophrenia, affective disorders and mood-incongruent psychotic symptoms. Br J Psychiatry. 2000 Nov;177:421-6.Full text Abstract
32. American Psychiatric Association. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia, third edition. Washington, DC: American Psychiatric Association; 2021.Full text
33. National Institute for Health and Care Excellence. Violence and aggression: short-term management in mental health, health and community settings. May 2015 [internet publication].Full text
34. Griswold KS, Del Regno PA, Berger RC. Recognition and differential diagnosis of psychosis in primary care. Am Fam Physician. 2015 Jun 15;91(12):856-63.Full text Abstract
35. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004 Feb;65(2):267-72. Abstract
36. Rector NA, Beck AT, Stolar N. The negative symptoms of schizophrenia: a cognitive perspective. Can J Psychiatry. 2005 Apr;50(5):247-57. Abstract
37. Bradizza CM, Stasiewicz PR. Integrating substance abuse treatment for the seriously mentally ill into inpatient psychiatric treatment. J Subst Abuse Treat. 1997 Mar-Apr;14(2):103-11. Abstract
38. Cheniaux E, Landeira-Fernandez J, Versiani M. The diagnoses of schizophrenia, schizoaffective disorder, bipolar disorder and unipolar depression: interrater reliability and congruence between DSM-IV and ICD-10. Psychopathology. 2009;42(5):293-8. Abstract
39. Jäger M, Haack S, Becker T, et al. Schizoaffective disorder: an ongoing challenge for psychiatric nosology. Eur Psychiatry. 2011 Apr;26(3):159-65. Abstract
40. Amador XF, Flaum M, Andreasen NC, et al. Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry. 1994 Oct;51(10):826-36. Abstract
41. Peuskens J. Good medical practice in antipsychotic pharmacotherapy. Int Clin Psychopharmacol. 1998 Mar;13(suppl 3):S35-41. Abstract
42. Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry. 1999;60 (Suppl 10):20-30. Abstract
43. Sajatovic M, Ross R, Legacy SN, et al. Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder: expert consensus survey part 2. Neuropsychiatr Dis Treat. 2018 Jun 8;14:1475-92.Full text Abstract
44. Ostinelli EG, Brooke-Powney MJ, Li X, et al. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev. 2017 Jul 31;7(7):CD009377.Full text Abstract
45. Zaman H, Sampson SJ, Beck AL, et al. Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database Syst Rev. 2017 Dec 8;12:CD003079.Full text Abstract
46. Ostinelli EG, Hussein M, Ahmed U, et al. Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev. 2018 Apr 10;4(4):CD009412.Full text Abstract
47. Kreyenbuhl J, Buchanan RW, Dickerson FB, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010 Jan;36(1):94-103.Full text Abstract
48. Schneider-Thoma J, Efthimiou O, Huhn M, et al. Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials. Lancet Psychiatry. 2018 Aug;5(8):653-63. Abstract
49. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013 Sep 14;382(9896):951-62.Full text Abstract
50. Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006654.Full text Abstract
51. Leucht S, Helfer B, Dold M, et al. Lithium for schizophrenia. Cochrane Database Syst Rev. 2015 Oct 28;2015(10):CD003834.Full text Abstract
52. European Medicines Agency. New measures to avoid valproate exposure in pregnancy endorsed. March 2018 [internet publication].Full text
53. Barnes TR, Drake R, Paton C, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020 Jan;34(1):3-78.Full text Abstract
54. Cottraux J, Note ID, Cungi C, et al. A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. Br J Psychiatry. 1995 Nov;167(5):635-41. Abstract
55. Bouvard M, Mollard E, Guerin J, et al. Study and course of the psychological profile in 77 patients expressing panic disorder with agoraphobia after cognitive behaviour therapy with or without buspirone. Psychother Psychosom. 1997;66(1):27-32. Abstract
56. Anaya C, Martinez Aran A, Ayuso-Mateos JL, et al. A systematic review of cognitive remediation for schizo-affective and affective disorders. J Affect Disord. 2012 Dec 15;142(1-3):13-21. Abstract
57. Turner DT, van der Gaag M, Karyotaki E, et al. Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. Am J Psychiatry. 2014 May;171(5):523-38. Abstract
58. Jauhar S, McKenna PJ, Radua J, et al. Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J Psychiatry. 2014 Jan;204(1):20-9. Abstract
59. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. March 2014 [internet publication].Full text
60. Hoffmann H, Jackel D, Glauser S, et al. Long-term effectiveness of supported employment: 5-year follow-up of a randomized controlled trial. Am J Psychiatry. 2014 Nov 1;171(11):1183-90.Full text Abstract
61. Katschnig H. Rehabilitation in schizophrenia; guidelines for including psychosocial measures [in German]. Wien Med Wochenschr. 1998;148(11-12):273-80. Abstract
62. Dieterich M, Irving CB, Bergman H, et al. Intensive case management for severe mental illness. Cochrane Database Syst Rev. 2017 Jan 6;1(1):CD007906.Full text Abstract
63. McGurk SR, Twamley EW, Sitzer DI, et al. A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry. 2007 Dec;164(12):1791-802.Full text Abstract
64. van Duin D, de Winter L, Oud M, et al. The effect of rehabilitation combined with cognitive remediation on functioning in persons with severe mental illness: systematic review and meta-analysis. Psychol Med. 2019 Jul;49(9):1414-25. Abstract
65. Wykes T, Huddy V, Cellard C, et al. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011 May;168(5):472-85.Full text Abstract
66. Eack SM, Greenwald DP, Hogarty SS, et al. One-year durability of the effects of cognitive enhancement therapy on functional outcome in early schizophrenia. Schizophr Res. 2010 Jul;120(1-3):210-6.Full text Abstract
67. Eack SM, Greenwald DP, Hogarty SS, et al. Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial. Psychiatr Serv. 2009 Nov;60(11):1468-76.Full text Abstract
68. Petrides G, Malur C, Braga RJ, et al. Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry. 2015 Jan;172(1):52-8.Full text Abstract
69. Zolezzi M. Medication management during electroconvulsant therapy. Neuropsychiatr Dis Treat. 2016 Apr 19;12:931-9.Full text Abstract
70. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry. 1988 Nov;39(11):1172-7. Abstract
71. Halbreich U, Kahn LS. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J Psychiatr Pract. 2003 Sep;9(5):344-53. Abstract
72. Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 14th ed. Chichester: Wiley-Blackwell; 2021.
73. Zhornitsky S, Stip E. Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review. Schizophr Res Treatment. 2012;2012:407171.Full text Abstract
74. Porcelli S, Balzarro B, Serretti A. Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol. 2012 Mar;22(3):165-82. Abstract
75. Choi KH, Wykes T, Kurtz MM. Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy. Br J Psychiatry. 2013 Sep;203(3):172-8.Full text Abstract
76. Matthews PRL, Horder J, Pearce M. Selective noradrenaline reuptake inhibitors for schizophrenia. Cochrane Database Syst Rev. 2018 Jan 25;1(1):CD010219.Full text Abstract
77. Dougall N, Maayan N, Soares-Weiser K, et al. Transcranial magnetic stimulation (TMS) for schizophrenia. Cochrane Database Syst Rev. 2015 Aug 20;(8):CD006081.Full text Abstract
78. National Institute for Health and Care Excellence. Transcranial magnetic stimulation for auditory hallucinations. September 2020 [internet publication].Full text
79. National Institute for Health and Care Excellence. Psychosis and schizophrenia in children and young people: recognition and management. October 2016 [internet publication].Full text
80. Jager M, Bottlender R, Strauss A, et al. Fifteen-year follow-up of ICD-10 schizoaffective disorders compared with schizophrenia and affective disorders. Acta Psychiatr Scand. 2004 Jan;109(1):30-7. Abstract
81. Torniainen M, Suvisaari J, Partonen T, et al. Cognitive impairments in schizophrenia and schizoaffective disorder: relationship with clinical characteristics. J Nerv Ment Dis. 2012 Apr;200(4):316-22. Abstract
82. Kane JM, McGlashan TH. Treatment of schizophrenia. Lancet. 1995 Sep 23;346(8978):820-5. Abstract
83. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17(2):325-51.Full text Abstract
84. Larsen TK, McGlashan TH, Moe LC. First-episode schizophrenia: I. Early course parameters. Schizophr Bull. 1996;22(2):241-56. Abstract
85. Malla AK, Norman RM, Manchanda R, et al. Status of patients with first-episode psychosis after one year of phase-specific community-oriented treatment. Psychiatr Serv. 2002 Apr;53(4):458-63. Abstract
86. Glassman AH. Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry. 2005;66(suppl 6):5-10. Abstract
87. Hawton K, Sutton L, Haw C, et al. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry. 2005 Jul;187:9-20.Full text Abstract
88. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005 Mar;62(3):247-53.Full text Abstract
89. Meltzer HY. Treatment of suicidality in schizophrenia. Ann N Y Acad Sci. 2001 Apr;932:44-58. Abstract
90. Bauer-Staeb C, Jörgensen L, Lewis G, et al. Prevalence and risk factors for HIV, hepatitis B, and hepatitis C in people with severe mental illness: a total population study of Sweden. Lancet Psychiatry. 2017 Sep;4(9):685-93.Full text Abstract
91. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD007253.Full text Abstract
92. Cubo E, Gracies JM, Benabou R, et al. Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol. 2001 Sep;58(9):1379-82. Abstract
93. Gray R, Gournay K. What can we do about acute extrapyramidal symptoms? J Psychiatr Ment Health Nurs. 2000 Jun;7(3):205-11. Abstract
94. Velamoor VR, Swamy GN, Parmar RS, et al. Management of suspected neuroleptic malignant syndrome. Can J Psychiatry. 1995 Nov;40(9):545-50. Abstract
95. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology. 2003 Jan;28(suppl 1):83-96. Abstract
96. Mukundan A, Faulkner G, Cohn T, et al. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006629.Full text Abstract
97. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res. 2004 Dec 1;71(2-3):195-212. Abstract
98. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68 (Suppl 1):20-7. Abstract
99. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001 Nov;158(11):1774-82. Abstract
100. Collaborative Working Group on Clinical Trial Evaluations. Adverse effects of the atypical antipsychotics. J Clin Psychiatry. 1998;59 (Suppl 12):17-22. Abstract
Use of this content is subject to our disclaimer